319 related articles for article (PubMed ID: 11295927)
1. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine B; Neonato MG; Girot R; Aractingi S
Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
3. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Olesen LH; Pedersen BB
Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
[TBL] [Abstract][Full Text] [Related]
4. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
Nzouakou R; Bachir D; Lavaud A; Habibi A; Lee K; Lionnet F; Hulin A; Jouault H; Préhu C; Roudot-Thoraval F; Girot R; Galactéros F
Acta Haematol; 2011; 125(3):145-52. PubMed ID: 21196716
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia.
Zargari O; Kimyai-Asadi A; Jafroodi M
Pediatr Dermatol; 2004; 21(6):633-5. PubMed ID: 15575845
[TBL] [Abstract][Full Text] [Related]
6. Are we underestimating the leukemogenic risk of hydroxyurea.
Al-Jam'a AH; Al-Dabbous IA; Al-Khatti AA; Esan FG
Saudi Med J; 2002 Nov; 23(11):1411-3. PubMed ID: 12506308
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
[TBL] [Abstract][Full Text] [Related]
8. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
[TBL] [Abstract][Full Text] [Related]
9. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
O'branski EE; Ware RE; Prose NS; Kinney TR
J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
[TBL] [Abstract][Full Text] [Related]
11. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
Soya E; Makowski C; Blaise S
Int Wound J; 2019 Aug; 16(4):897-902. PubMed ID: 30916480
[TBL] [Abstract][Full Text] [Related]
12. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease.
Huang Y; Ananthakrishnan T; Eid JE
Am J Hematol; 2003 Oct; 74(2):125-6. PubMed ID: 14508799
[TBL] [Abstract][Full Text] [Related]
14. When should hydroxyurea be used for children with sickle cell disease?
Mueller BU
Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
[No Abstract] [Full Text] [Related]
15. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
17. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity.
Halabi-Tawil M; Lionnet F; Girot R; Bachmeyer C; Lévy PP; Aractingi S
Br J Dermatol; 2008 Feb; 158(2):339-44. PubMed ID: 18047512
[TBL] [Abstract][Full Text] [Related]
18. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
Tripathi A; Jerrell JM; Stallworth JR
Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
[TBL] [Abstract][Full Text] [Related]
19. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
